Bausch Health Expands Dermatology Portfolio with Online Launch of Biafine® in the U.S.
Event summary
- Bausch Health's Ortho Dermatologics launched Biafine® Skin Recovery Emulsion for online ordering in the U.S. on April 14, 2026.
- The product, developed in France in 1971, is available through select online channels, including Amazon.
- Dermatology practices can provide Biafine® through Ortho Dermatologics Direct platform for in-office access.
- Biafine® is marketed as a cosmetic skincare product in the U.S., designed to support skin barrier function and hydration.
The big picture
Bausch Health's move to launch Biafine® online aligns with the broader trend of pharmaceutical companies expanding direct-to-consumer sales channels. The strategy aims to capitalize on the growing demand for dermatological skincare products, particularly those with clinical backing. By leveraging its existing Ortho Dermatologics Direct platform, Bausch Health is integrating digital distribution with traditional in-office dermatology practices, potentially enhancing patient access and compliance.
What we're watching
- Market Penetration
- How Bausch Health will leverage Amazon and other online channels to drive Biafine® adoption among U.S. consumers.
- Competitive Positioning
- Whether Biafine® can differentiate itself in the crowded U.S. skincare market dominated by established brands.
- Revenue Impact
- The pace at which online sales of Biafine® contribute to Ortho Dermatologics' revenue growth.
Related topics